Driehaus Capital Management’s Sage Therapeutics SAGE Stock Holding History

Driehaus Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,121	Closed	-$441K	–	501
2018 Q3	$441K	Sell	3,121 -6,920	-69%	-$1.07M	0.01%	411
2018 Q2	$1.57M	Buy	10,041 +501	+5%	+$78.7K	0.05%	297
2018 Q1	$1.54M	Sell	9,540 -49	-0.5%	-$8.32K	0.05%	294
2017 Q4	$1.58M	Buy	+9,589	New	+$930K	0.06%	288
2017 Q3	–	Sell	-11,139	Closed	-$887K	–	579
2017 Q2	$887K	Sell	11,139 -9,927	-47%	-$718K	0.03%	361
2017 Q1	$1.5M	Sell	21,066 -3,087	-13%	-$181K	0.05%	309
2016 Q4	$1.23M	Buy	+24,153	New	+$1.14M	0.04%	322
2016 Q3	–	Sell	-136,089	Closed	-$4.1M	–	592
2016 Q2	$4.1M	Buy	136,089 +82,709	+155%	+$2.76M	0.15%	152
2016 Q1	$1.71M	Buy	53,380 +27,796	+109%	+$978K	0.06%	304
2015 Q4	$1.49M	Buy	+25,584	New	+$1.27M	0.05%	337
2015 Q3	–	Sell	-80,055	Closed	-$5.84M	–	603
2015 Q2	$5.84M	Sell	80,055 -32,544	-29%	-$2.09M	0.2%	113
2015 Q1	$5.66M	Buy	112,599 +58,735	+109%	+$2.53M	0.2%	133
2014 Q4	$1.97M	Buy	+53,864	New	+$2.01M	0.08%	313

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Driehaus Capital Management's SAGE Position: Q4 2018 in Review

Driehaus Capital Management sold out of Sage Therapeutics (SAGE) in Q4 2018, closing a stake of 3,121 shares — an estimated $441K sold.

Driehaus Capital Management first reported a position in SAGE in Q4 2014 and held it in 13 quarters. The position peaked at $5.84M in Q2 2015. 248 funds tracked by Wall St. Rank hold SAGE as of Q4 2018.

Driehaus Capital Management reported no remaining Sage Therapeutics position as of Q4 2018 after selling out during the quarter.
Driehaus Capital Management sold 3,121 Sage Therapeutics shares in Q4 2018, an estimated $441K.
Driehaus Capital Management first reported a position in Sage Therapeutics in Q4 2014 and held it in 13 quarters.
Driehaus Capital Management's Sage Therapeutics position peaked at $5.84M in Q2 2015.
248 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2018.

Based on Driehaus Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.